Patients with rheumatoid arthritis (RA) tolerated a novel Janus kinase/Roh-associated protein kinase (JAK-ROCK) inhibitor without typical side effects. Phase 2 clinical trial at nine hospitals and ...

VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...

Finding the right medication for rheumatoid arthritis isn't easy, and a newer pill against the disease carries higher risks of heart attack, stroke and cancer than older RA drugs, a new clinical trial ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

Please provide your email address to receive an email when new articles are posted on . The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...

Patients taking tofacitinib (Xeljanz) in the drug's late-stage and post-marketing studies were more likely than those on placebo to gain weight and body mass index (BMI) points, pooled data from more ...

Previous, smaller studies had found that patients tended to gain weight while on the Janus kinase (JAK) inhibitor tofacitinib. This study, funded by tofacitinib's manufacturer, analyzed data from more ...